Flerie Invest AB has launched a mandatory cash offer for Nanologica AB, seeking to acquire all outstanding shares at a price of SEK 1.00 per share.

Information on the Target

Nanologica AB (publ) is a prominent player in the life science sector, focusing on innovative advancements and solutions in the field. The company has been recognized for its pioneering research and development efforts aimed at improving healthcare outcomes and providing high-quality therapeutic options.

As of May 2025, Flerie Invest AB, a wholly owned subsidiary of Flerie AB, sought to enhance its stake in Nanologica through a mandatory cash offer. At the time of the offer, Flerie held approximately 43.25% of the company’s total shares and voting rights, indicating a significant level of control and interest in the target’s future.

Industry Overview

Sweden's life sciences industry has been experiencing robust growth, driven by increased investment in research and development, advancements in technology, and a supportive regulatory envi